- Home
- RPRX vs CHRW Comparison
RPRX vs CHRW Comparison
Compare RPRX & CHRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- CHRW
- Stock Information
- Founded
- RPRX 1996
- CHRW 1905
- Country
- RPRX United States
- CHRW United States
- Employees
- RPRX N/A
- CHRW N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- CHRW Oil Refining/Marketing
- Sector
- RPRX Health Care
- CHRW Consumer Discretionary
- Exchange
- RPRX Nasdaq
- CHRW Nasdaq
- Market Cap
- RPRX 15.6B
- CHRW 14.8B
- IPO Year
- RPRX 2020
- CHRW 1997
- Fundamental
- Price
- RPRX $37.03
- CHRW $127.49
- Analyst Decision
- RPRX Strong Buy
- CHRW Buy
- Analyst Count
- RPRX 4
- CHRW 21
- Target Price
- RPRX $44.50
- CHRW $132.15
- AVG Volume (30 Days)
- RPRX 3.5M
- CHRW 1.5M
- Earning Date
- RPRX 11-05-2025
- CHRW 10-29-2025
- Dividend Yield
- RPRX 2.38%
- CHRW 1.97%
- EPS Growth
- RPRX 54.86
- CHRW 58.22
- EPS
- RPRX 2.32
- CHRW 4.40
- Revenue
- RPRX $2,305,243,000.00
- CHRW $17,012,580,000.00
- Revenue This Year
- RPRX $35.14
- CHRW N/A
- Revenue Next Year
- RPRX $1.24
- CHRW $3.83
- P/E Ratio
- RPRX $15.92
- CHRW $28.65
- Revenue Growth
- RPRX 3.02
- CHRW N/A
- 52 Week Low
- RPRX $24.05
- CHRW $84.68
- 52 Week High
- RPRX $38.00
- CHRW $138.00
- Technical
- Relative Strength Index (RSI)
- RPRX 61.20
- CHRW 45.06
- Support Level
- RPRX $35.23
- CHRW $125.76
- Resistance Level
- RPRX $36.36
- CHRW $129.86
- Average True Range (ATR)
- RPRX 0.63
- CHRW 2.91
- MACD
- RPRX 0.11
- CHRW -1.13
- Stochastic Oscillator
- RPRX 95.38
- CHRW 27.25
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About CHRW C.H. Robinson Worldwide Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 60% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (30%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.